Mira-55: A Promising New Frontier in Pain and Neuropsychiatric Treatment
Beyond its anti-inflammatory and analgesic properties, previous preclinical studies have unveiled broader potential for Mira-55 in neurological and neuropsychiatric domains. Research has shown that Mira-55 enhanced memory performance and reduced anxiety-related behaviors, opening doors for its application in conditions beyond chronic pain.
Introducing Mira-55: A Breakthrough in Cannabinoid Therapeutics
Mira-55 stands at the forefront of next-generation cannabinoid analogs. This innovative compound has been meticulously engineered to selectively activate CB2 cannabinoid receptors, which are primarily associated with anti-inflammatory and analgesic effects. Crucially, Mira-55 achieves these therapeutic benefits while minimizing the psychoactive side effects typically linked with CB1 receptor activation.
A significant milestone for Mira-55’s commercial viability and favorable regulatory profile is its classification by the U.S. Drug Enforcement Administration (DEA). Following a thorough scientific review, the DEA determined that Mira-55 is not classified as a controlled substance, a decision that underscores its long-term market potential.
About Mira-55
Mira-55 is a next-generation analog of marijuana engineered to selectively activate CB2 cannabinoid receptors associated with anti-inflammatory and analgesic effects while minimizing CB1-related psychoactivity. Following scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance, supporting its favorable regulatory profile and long-term commercial potential.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a dynamic clinical-stage pharmaceutical company dedicated to developing novel therapies for a range of challenging conditions, including neurologic, neuropsychiatric, and metabolic disorders. Headquartered in Miami, Florida, MIRA Pharmaceuticals boasts a robust pipeline of promising candidates.
Key assets in their portfolio include:
- Mira-55: As detailed above, this non-psychoactive cannabinoid analog is being developed for chronic inflammatory pain, with additional preclinical data supporting its potential for anti-anxiety and memory-enhancing activities.
- Ketamir-2: An NMDA-receptor antagonist, Ketamir-2 is currently in development for the treatment of neuropathic pain.
- SKNY-1: This oral drug candidate is targeting significant public health challenges: obesity and smoking cessation.
MIRA Pharmaceuticals continues to advance its mission to bring innovative and effective treatments to patients in need, leveraging cutting-edge science to address critical unmet medical demands.
